Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced participation in upcoming conferences by its CFO and CBO. The CFO, Hans van Houte, and CBO, Jason Kantor, will be attending Leerink Partners Global Biopharma Conference on March 12 and Barclays Global Healthcare Conference on March 13, 2024. The fireside chat at the Barclays conference will be webcast live and accessible via the Nurix website.

SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Hans van Houte, Nurix’s chief financial officer, and Jason Kantor, Ph.D., Nurix’s chief business officer will participate in the following conferences in March:

• Leerink Partners Global Biopharma Conference 2024
  One-on-one meetings only: Tuesday, March 12, 2024
  

• Barclays Global Healthcare Conference
  Fireside chat: Wednesday, March 13, 2024, from 4:05 – 4:30 p.m. ET
  

The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When will Hans van Houte and Jason Kantor participate in the Leerink Partners Global Biopharma Conference?

Hans van Houte and Jason Kantor will participate in one-on-one meetings at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024.

What type of event will Jason Kantor be part of at the Barclays Global Healthcare Conference?

Jason Kantor will be part of a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 13, 2024, from 4:05 – 4:30 p.m. ET.

Where can the live webcast of the fireside chat be accessed?

The live webcast of the fireside chat can be accessed via a link in the Investors section of the Nurix website under Events and Presentations.

For how long will the archived webcast of the fireside chat be available?

The archived webcast of the fireside chat will be available on the Nurix website for 30 days after the event.